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Abstract: This article reviews the current and most neurologic uses of botulinum neurotoxin 
type A (BoNT-A), beginning with relevant historical data, neurochemical mechanism at 
the neuromuscular junction. Current commercial preparations of BoNT-A are reviewed, as 
are immunologic issues relating to secondary failure of BoNT-A therapy. Clinical uses are 
summarized with an emphasis on controlled clinical trials (as appropriate), including facial 
movement disorders, focal neck and limb dystonias, spasticity, hypersecretory syndromes, 
and pain.
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Botulinum neurotoxins have evolved in the past ﬁ  fty years from a reputation for lethality 
and potential as weaponry in biological warfare to safe in-ofﬁ  ce treatment for a host 
of medical conditions ranging from wrinkles to sphincteric dysfunction. The effects of 
these toxins at the neuromuscular junction lends themselves to neurologic diseases of 
muscle overactivity, particularly abnormalities of muscle control. Additional studies 
have pointed to therapeutic efﬁ  cacy of botulinum toxins in hypersecretory and painful 
disorders. This review focuses on botulinum neurotoxin type A (BoNT-A) in com-
monly used therapies for neurological diseases.
History and background
Botulism was ﬁ  rst described in the early 19th century following an outbreak of poisonings 
from the ingestion of blood sausages. The term “botulism” owes its origins to this 
association, as botulus is latin for “sausage” (Erbguth 1996). By the end of the 1800s, 
the organism Clostridium botulinum was isolated after a case of fatal food poisonings, 
and a neurotoxic mechanism was postulated. Victims were described as suffering 
from a rapidly progressive paralysis with intact cognition, ultimately causing fatal 
respiratory insufﬁ  ciency (van Ermengem 1979). The canning of food for long-term 
preservation led to a number of botulism outbreaks in the early 20th century in the 
United States. The industry reacted with better canning techniques (Meyer 1956) and 
doctors attempted to counter the toxin effects. The development of antisera capable 
of neutralizing the toxin effect in one outbreak with lack of efﬁ  cacy in another led 
to discovery of differing immunologic serotypes (Sakaguchi 1983). Botulinum toxin 
type A was puriﬁ  ed and crystallized in the post-World-War II search for biological 
weaponry measures and countermeasures by United States Army researchers (Schantz 
and Johnson 1997).
Botulism remains a deadly illness that can result from ingestion, enteric bacterial 
overgrowth, or wound infection. Food-borne botulism causes regular outbreaks with 
symptoms ranging from mild diplopia to muscle weakness and respiratory compromise 
(Silberstein 2004). Infantile botulism results from ingestion of Clostridium spores, is 
associated with honey intake, and is a cause of acquired hypotonia (Shapiro et al 1998). 
Clostridium spores are present in soil, but may also contaminate illicit intravenous Neuropsychiatric Disease and Treatment 2007:3(6) 786
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drugs, with the typical syndrome of descending weakness 
resulting from intramuscular injections (wound botulism) 
(Cooper et al 2005).
Despite the dangers of botulism, therapeutic use of 
BoNT-A was begun in the late 1960s, when an ophthal-
mologist, Dr. Alan B. Scott, successfully injected rhesus 
monkey extraocular muscles to correct strabismus. His 
results were later replicated in humans (Scott et al 1973). 
Studies showed efﬁ  cacy in the treatment of muscle control 
syndromes such as blepharospasm and cervical dystonias. 
Further puriﬁ  cation of BoNT-A led to the US Food and 
Drug Administration (FDA) approval for treatment of 
blepharospasm, strabismus, and facial nerve dysfunction 
in 1989. Commercially available BoNT-A was marketed 
by Allergan, Inc. (Irvine, CA) as BOTOX®, and by Ipsen, 
Ltd. (Slough, UK) as Dysport®. Xeomin®, a protein-free 
BoNT-A manufactured by Merz Pharmaceuticals GmbH 
(Frankfurt-am-Main, Germany), and Prosigne® (Lanzhou 
Biologic Products Institute, China), a Chinese formulation 
of BoNT-A, are approved for usage in Germany (Xeomin®) 
and parts of Asia and South America (Prosigne®). In 2000, 
cervical dystonia became an FDA-approved indication for 
both serotypes A and B of botulinum neurotoxin. Current 
FDA-approved uses of BoNT-A also include the reduction 
of glabellar lines and the treatment of axillary hyperhidrosis 
(Cheng et al 2006). Off-label in the United States include 
the treatment of sialorrhea, muscle control disorders (limb 
dystonias and spacticity), and painful disorders (low back 
pain, headache).
Mechanism
The anaerobic bacillus Clostridium botulinum secretes 
seven known serotypes of botulinum toxin, typed alphabeti-
cally A-G. The toxins are 150 kd single chain polypeptides 
which undergo protease-mediated nicking to form heavy 
and light chains (Montecucco et al 1996). Heavy chains 
irreversibly bind to the SV2 receptor on the presynaptic 
membrane (Dong et al 2006), allowing for entry of the 
toxin into the axon terminal (Simpson 1980). Once inside 
the axon, the light chains act to impede exocytosis of 
acetylcholine. Speciﬁ  cally, the toxins are zinc-dependent 
metalloproteases that interfere with portions of the SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor) protein complex (Hay 2001). The SNARE 
complex allows for fusion of neurotransmitter-containing 
intra-axonal vesicles with the presynaptic membrane, 
resulting in extrusion of acetylcholine into the synaptic 
cleft. Botulinum toxin type A is responsible for cleavage 
of the SNARE component SNAP-25 (25 kilodalton 
synaptosomal- associated protein) molecule (Blasi et al 
1993), whereas botulinum toxin type B cleaves SNARE 
component synaptobrevin (vesicle-associated membrane 
protein or VAMP). Only types A and B have been utilized 
for commercial applications.
Botulinum neurotoxins reduce presynaptic outﬂ  ow of 
acetylcholine at the neuromuscular junction, with a con-
sequent diminution in muscle contraction. A basal rate of 
acetylcholine secretion across the synaptic cleft occurs 
continuously, with each packet of acetylcholine depolar-
izing the post-synaptic membrane to create miniature end 
plate potentials (MEPPs). MEPPs summate to maintain the 
motor end-plate potential (EPP). Botulinum neurotoxins 
prevent acetyclcholine secretion, reducing the frequency and 
quantity, but not amplitude of MEPPs. (Maselli et al 1992) 
BoNT-A effects a reduction in MEPP frequency twice that of 
BoNT-B. (Simpson 2000) The motor EPP is reduced below 
the muscle membrane threshold and the ability to generate 
muscle ﬁ  ber action potentials and subsequent contraction is 
diminished. The muscle ﬁ  bers supplied by the nerve terminal 
affected by botulinum toxins are effectively denervated (with 
dose and diffusion-gradient -related reduction in the size of 
muscle ﬁ  bers (Borodic et al 1994)), although the gross his-
tologic appearance of the neuromuscular junction remains 
normal (Duchen and Strich 1968).
Once acetylcholine release is effectively impaired from 
the axon terminal, or terminal bouton, the process of recovery 
begins. New nerve sprouts emerge from the nodes of Ranvier 
in the region preceding the presynaptic membrane. These 
may begin in as little as one week after botulinum neurotoxin 
administration in the case of slow-twitch muscle ﬁ  bers, or up to 
6 weeks for fast-twitch muscles (Duchen 1971). Sprouts form 
new neuromuscular junctions and new endplates with adjacent 
muscle. Acetylcholine is released from new nerve terminals, 
and as new endplates mature, functional recovery begins. 
Muscle ﬁ  ber atrophy may occur prior to full maturation of the 
motor end plates. Eventually, the SNARE protein complex is 
regenerated, acetylcholine release resumes from the original 
nerve terminal, and axon sprouts retract (de Paiva 1999). The 
functional paralysis usually lasts for 3–4 months.
Formulations, safety, and adverse 
effects
The commercial formulation of BoNT-A as BOTOX® is 
packaged as a vacuum-dried powder, 100 units per vial. 
Speciﬁ  c activity of BOTOX® is rated at 20U/ng. The 150 kDa 
botulinum neurotoxin molecule is complexed with 600kDa Neuropsychiatric Disease and Treatment 2007:3(6) 787
Neurologic uses of botulinum neurotoxin type A
hemagglutinizing and non-hemagglutinizing non-toxic proteins 
(Dressler and Hallett 2006) for a total concentration of 5 ng per 
100 units in its current formulation. 0.5 mg of human albumin 
is present in each vial as an excipient. Storage at 2 ºC–8 ºC 
is recommended. The shelf life is 2 years. To administer the 
medication, the vial is reconstituted with 1–4 ml of normal 
saline (0.9% NaCl), and given intramuscularly within 4 hours 
of reconstitution (BOTOX® package insert 2004). Retail cost 
is approximately $600 US per vial.
Dysport® is distributed in 500U vials as a freeze-dried 
powder with 0.125 mg albumin and 2.5 mg lactose as 
excipients. Speciﬁ  c activity of Dysport® is rated at 40U/ng. 
Protein content is 12.5 ng/vial. Storage and reconstitution are 
similar to BOTOX® (Dysport® package insert 2005).
Xeomin® is packaged in 100U vials as a freeze-dried 
powder with handling and administration similar to BOTOX® 
(Jost et al 2007). Prosigne® formulation, handling and 
administration requirements were not available as of this 
writing. Table 1 compares the commercial BoNT-As based 
on available data.
Dosing conversions between various preparations of 
BoNT-A is not necessarily intuitive. Studies of Xeomin® and 
Prosigne® use unit dosing comparable (1:1) with BOTOX® 
(Rieder et al 2007; Wohlfarth et al 2007). BOTOX® to Dys-
port® dosing has been suggested to be anywhere from 1:2 to 
1:6 (Rosales et al 2006). Dosing of Dysport® should be based 
on trials conducted with that formulation of BoNT-A rather 
than an absolute conversion ratio from BOTOX®.
Athough botulinum toxin is one of the most deadly 
neurotoxins known (Osbourne et al 2007), the therapeutic 
administration of BoNT-A is quite safe. Studies of intra-
muscular administration of BoNT-A in laboratory-based 
non-human primates showed an LD50 of 38U/kg in a 
study of eight rhesus monkeys (Scott and Suzuki 1988), 
and a minimal lethal dose of 24U/kg in adult cynomolgus 
monkeys (BOTOX® package insert). For a 75 kg man, this 
works out to be 1800U. The LD50 in conventional labora-
tory mouse assay units has not been consistently established 
(Settler 2002).
Both serious and more benign side effects have been 
reported with BoNT-A administration. Injections are 
local, intramuscular, and systemic complications are rare 
(BOTOX® package insert 2004). More concerning events 
include ptosis and diplopia for strabismus, and dysphagia 
from injection for cervical dystonia (reported in up to 24% of 
patients in one trial (Commella and Thompsen 2006)). This 
latter event is most disturbing for relatively high frequency 
and for increased risk of aspiration pneumonia. Other adverse 
events include cough, fever, upper respiratory infection, ﬂ  u-
like malaise, headache, and very commonly, injection site 
reactions (erythema, swelling) and bruising. Hypersensitiv-
ity reactions such as edema and dyspnea have been noted. 
Anaphylaxis has been reported in one patient who received 
BOTOX® mixed with lidocaine. Spontaneous death after 
botulinum toxin A administration has been reported, but a 
causal link has not been established. A meta-analysis of con-
trolled trials for BOTOX® efﬁ  cacy in a variety of conditions 
concluded that focal weakness local to the area of injection 
were the only consistent events not reﬂ  ected in controls 
(Naumann and Jankovic 2004). Generally, these events were 
mild to moderate in severity, temporary, and related to the 
medication’s mechanism of action. Strategies for avoiding 
focal weakness include minimal dilution of the BoNT-A 
(eg, 100U/1cc for BOTOX®), this prevents diffusion of the 
neurotoxin outside the target location. Division of doses 
with to multiple sites allows for less neurotoxin in a single 
depot in muscle, with less focal functional denervation, and 
a presumed reduction in focal weakness.
Tolerance and immunogenicity
An antibody-mediated tolerance has been invoked as a 
rationale for secondary failure of BoNT-A after initial good 
response to treatment. BoNT-A and the proteins complexed 
with the neurotoxins provide sites of antigenic stimulation 
and ultimately antibody formation, as has been demonstrated 
experimentally with Western Blot (Hanna and Jancovic 
2000) or ELISA. The commercially available assessment 
of antibodies is done using a mouse lethality assay (MLA), 
Table 1 BoNT-A commercial formulations
Trade Name  BOTOX® Dysport® Xeomin® Prosigne®
Manufacturer  Allergan, Inc.  Ipsen, LTD.  Merz Pharmaceuticals  Lanzhou Biological Products Institute
Country of origin  USA  UK  Germany  China
Protein amount  5ng/100U  12.5ng/500U  None  ?
BOTOX® *Dosing conversion  1:1  1:2–1:6  1:1  1:1
Based on BOTOX Product Insert 2004; Dysport® product insert 2005; Markey 2004; Jost et al 2007; Tang and Wan 2000
*See textNeuropsychiatric Disease and Treatment 2007:3(6) 788
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or the more sensitive mouse hemidiaphragmatic paralysis 
model (also known as a mouse protection assay or MPA) 
(Critchﬁ  eld 2002). In the MLA, the patient’s serum is incu-
bated with a lethal dose of botulinum toxin, then injected 
into the peritoneal cavities of mice. Laboratory mouse death 
ensues unless presumed blocking antibodies prevent botuli-
num neurotoxin function. The MPA uses the same method of 
serum incubation with botulinum toxin, which is injected in 
a bath of excised mouse phrenic nerve and hemidiaphragm 
where amplitude of contraction to electrical stimulation is 
measured. Failure to produce a 50% or greater decrement 
in contraction amplitude is evidence of antibodies to the 
neurotoxin (Dressler et al 2000).
Antibodies to BoNT-A have been noted in 36%–60% 
of patients with secondary failure of BOTOX® for cervical 
dystonia (Anderson et al 1992; Jancovic and Schwartz 1995), 
and in up to 100% for focal dystonias (Jancovic and Schwartz 
1995). These ﬁ  gures are from relatively small series of 
patients. Subsequent analysis suggested that short intervals 
between repeated injections and dosage of BOTOX® cor-
related with antibody development (Dressler and Dimberg 
2000). All of these studies were of the BOTOX® formulation 
prior to 1998.
In 1998, the amount of neurotoxin complex protein in 
BOTOX® was reduced from 25 ng/100U to 5 ng/100U, with 
a presumed reduction in antigenic potential. Jankovic et al 
(2003), prospectively tested 119 patients with minimal or no 
response to the current formulation of BoNT-A treatment for 
cervical dystonia on two consecutive visits for antibodies 
using the mouse lethality assay. None of the patients had 
antibodies noted by a positive MLA. In contrast, 4 of 42 
patients treated with the original (FDA-approved 1989–98) 
formulation of botulinum toxin meeting the same criteria for 
treatment failure had antibodies present. Although the risk of 
antibody formation does appear to be signiﬁ  cantly decreased 
with the present formulation of BOTOX®, several cases of 
antibody-associated treatment failure have been reported 
(Dressler 2004; Dressler and Saberi 2007).
Botulinum toxin A in clinical 
neurology
BoNT-A, by acting at the neuromuscular junction to 
reversibly alter muscle tone and selectively functionally 
denervate muscle, is used extensively in disorders of muscle 
overactivity, such as facial movement disorders, limb and 
neck dystonias, and spasticity. Botulinum neurotoxins are 
also effective at inhibiting acetylcholine release at sites other 
than neuromuscular junction (Dressler 2005), leading to 
effective treatments for hypersecretory syndromes, especially 
sialorrhea and hyperhidrosis. Lastly, painful syndromes such 
as headache and low back pain have been treated with some 
success by BoNT-A injections.
Facial movement disorders
With early research for botulinum toxin focusing on selective 
denervation for dysconjugate gaze, overactivity of muscles 
involving eye and mouth closure were targeted next. 
Blepahrospasm is a focal dystonia of eyelid closure, which 
can be quite disabling and, in more extreme cases, render the 
sufferer functionally blind (Ben Simon and McCann 2005). 
Patients may have a noticeable increased frequency in blink 
rate, endure spasms of eyelid closure, or have continuous lid 
closure with signiﬁ  cantly impaired voluntary eyelid opening. 
Oromandibular dystonias involve the muscles of mastication, 
particularly masseter, temporalis, and pterygoid muscles, 
and can result in disabling jaw deviation, jaw clenching or 
protrusion (Bhidayasiri et al 2006). Tongue and pharyngeal 
muscles may also be involved, and the affected patient 
may be unable to speak, chew, or swallow effectively. 
Meige syndrome describes oromandbular dystonia and 
blepharospasm in combination (Tolosa 1988). Hemifacial 
spasms are non-dystonic paroxysms of muscle twitching on 
one side of the face, often due to vascular compression of the 
7th cranial nerve, variably including upper and lower facial 
nerve-innervated musculature (Tan 2002).
Blepharospasm
Effective management of blepharospasm with BoNT-A 
was established largely via small, uncontrolled, open-label 
trials (Scott et al 1985; Kennedy et al 1989; Borodic and 
Cozzolino) prior to United States FDA approval of BOTOX®. 
A recent Cochrane Review and metanalysis of BoNT-A 
and blepahrospasm (Costa et al 2005) found a paucity of 
blinded, controlled trials consisting of small numbers only. 
Review of pooled case-controlled data of over 2500 patients 
demonstrated a 90% efﬁ  cacy rate of BoNT-A injections in 
blepharospasm (Jost and Kohl 2001). Most published clinical 
research was conducted with BOTOX®, but Dysport® has 
also proven efﬁ  cacy in placebo-controlled and head-to-head 
settings comparable to BOTOX® (Truong 2005). Likewise, 
a trial of equal units of Xeomin® (NT 201) vs BOTOX® 
(Wohlfarth et al 2007) yielded comparable success for 
blepharospasm management.
The large volume and duration of practitioner experience 
has distilled into recommended injection strategies for 
blepharospasm. Up to 20U per eye of BOTOX® are injected Neuropsychiatric Disease and Treatment 2007:3(6) 789
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into the orbicularis oculi at 2.5–5.0U per site through a 27–30 
gauge needle. Two injections are made at the upper lid near 
the canthus medially and laterally to avoid the bulk of the 
levator palpebrae muscle and consequent ptosis (Bhidayasiri 
et al 2006). Two lower lid injections are conducted one in the 
middle portion, and one at the lower lateral canthus. Avoid-
ance of the medial canthus spares the nasolacrimal appara-
tus (Bhidayasiri et al 2006). Dysport® dosing ranges from 
40–120U per eye in clinical trials (Truong 2005). Adverse 
effects of periocular BoNT-A injection include ptosis, dry 
eyes, and diplopia. Avoidance of the medial aspect of the 
lower lid, and injection into the pre-tarsal region rather than 
the preseptal orbicularis oculi may increase efﬁ  cacy and 
reduce complications (Cakmur et al 2002).
Oromandibular dystonia
Oromandibular dystonias have responded poorly to 
systemic medications (clonazepam, anticholinergics, and 
antispasmodics) (Greene et al 1988), but mostly small open-
label trials of BoNT-A indicate signiﬁ  cant improvement 
with neurotoxin injection. Most studies have been done 
using BOTOX®, but similar effects have been obtained in 
small series with Dysport® (Van der Bergh et al 1995). In a 
prospective uncontrolled study of 162 patients followed an 
average of 4.4 years, Tan and Jankovic (Tan and Jancovic 
1999) noted a mean duration of effect of 16.4 weeks and global 
improvement effect rated as a 3.1/4. Greatest improvement 
was seen in patients with primarily jaw-closure dystonias. 
Jaw opening dystonias proved more difﬁ  cult to treat and had 
a 40% incidence of dysarthria and dysphagia (relative to only 
19% with treated jaw closure dystonias.)
Injection strategies for BoNT-A in oromandibular dystonias 
should be individualized to target the speciﬁ  c anatomy of the 
dystonic movements. Jaw closure dystonia injections should 
include the masseters, and temporalis muscles, at starting 
doses of 40–50U BOTOX® or 100U Dysport® each; medial 
pterygoids may also be targeted with 20U BOTOX® or 30U 
Dysport® (Bhidayasiri et al 2006). Jaw opening dystonias 
should focus primarily on the lateral pterygoids, with 
starting doses of 20U BOTOX® (Blitzer et al 1989) or 60U 
Dysport® (Bhidayasiri et al 2006). The submentalis complex 
(mylohyoid, geniohyoid, and anterior digastricus) has been 
targeted as well, with a recommended starting dose of 20U 
BOTOX® or 90U Dysport® (Bhidayasiri et al 2006). An aware-
ness of the anatomical relationships of these muscles is crucial 
to avoid nearby secretory and vascular structures. The use of 
electromyography has been suggested for muscles that are not 
surface-palpable, but has not been validated.
Hemifacial spasm
Hemifacial spasm (HFS) has been treated with oral anti-
cholinergic, antispasmodic, and anticonvulsive medications 
(Kemp and Reich 2004) with small degrees of success. 
Surgical microvascular decompression has been reported 
to offer long-term relief in up to 95% of treated patients 
(Chung et al 2001), but there may be signiﬁ  cant morbidity 
and mortality from invasive intracranial procedures. BoNT-A 
offers the hope of symptom reduction or relief without the 
adverse effects of surgery. Although BoNT-A is routinely 
used as a treatment for HFS, a thorough scientiﬁ  c validation 
of efﬁ  cacy is lacking. A meta-analysis involving BoNT-A 
(Costa et al 2005) revealed only a single well-designed, 
prospective, blinded, placebo-controlled trial of 11 patients 
(treated with BOTOX®) (Yoshimura et al 1992), in addition 
to many larger open-label trials, concluding that the medi-
cation is safe in HFS and supporting the conclusions of the 
uncontrolled studies that efﬁ  cacy ranges from 76%–100%. 
Peak effect was reported at 2 weeks and effect duration was 
nearly 3 months (Yoshimura et al 1992). Other BoNT-A 
preparations, Dysport® and Prosigne®, were evaluated to 
have similar success rates as BOTOX® in small random-
ized, uncontrolled trials but with increased side effects noted 
(Sampaio et al 1997; Rieder et al 2007).
Therapeutic administration of BoNT-A for HFS is similar 
to strategies described for blepharospasm, with the addition 
of targeting very small doses to lower facial muscles as well. 
In addition to the 4 orbicularis oculi injections suggested 
for blepharospasm treatment, zygomaticus major, buccina-
tor, and depressor anularis oris have been targeted by some 
authors, at 1–2U BOTOX® or 3–6U Dysport® per muscle 
(Frei et al 2006). Adverse effects include dry eyes, ptosis, and 
facial or mouth drooping. Other experts suggest staging upper 
facial (periorbital) injections ﬁ  rst, with lower facial injections 
only on 2-week follow-up after careful discussion with the 
patient about likelihood of signiﬁ  cant lower facial drooping, 
including lip biting and asymmetric smile (Mauriello 2002). 
Precautions for injection include those recommended for 
BoNT-A injections for blepharospasm, but also to take care 
to avoid injections into elevators or the lips or mouth such as 
levator labii superioris, levator angularis oris, and orbicularis 
oris (Comella and Pullman 2004).
Focal neck and limb dystonias
Botulinum neurotoxins have been applied with particular suc-
cess to the treatment of focal neck and appendicular dystonias 
(Ward et al 2006). Cervical dystonias are involuntary move-
ments or postures of the head, neck, and shoulders. There Neuropsychiatric Disease and Treatment 2007:3(6) 790
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may be head rotation (torticollis), neck ﬂ  exion (anterocollis) 
or extension (retrocollis), or lateral deviation (laterocollis). 
Movements may be spasmodic, rhythmic (tremoring), or 
ﬁ  xed. Pain accompanies cervical dystonia in the major-
ity of patients (Lew 2002). Focal dystonias can produce 
undesirable torsional, ﬂ  exion or extension movements of 
the limbs or digits, limiting manual dexterity in the upper 
extremities, and impairing walking in the lowers (Tarsy and 
Simon 2006). The most reported, and often most disabling, 
are the occupational dystonias, particularly writer’s cramp 
and musicians’ dystonia. Unwanted hand postures occur in 
relation to particular tasks, often writing or playing musical 
instruments (Karp 2004).
Cervical dystonia
Treatment of cervical dystonia (CD) has been the most 
studied of all the potential applications of BoNT-A. Early 
studies showed safety and efﬁ  cacy in small cohorts (Tsui et al 
1985; Tsui et al 1986) with a minority of patients reporting 
transient neck weakness or dysphagia. A meta-analysis of 
cervical dystonia treatment trials evaluating BoNT-A from 
1986–2002 (Costa et al 2005) revealed 13 controlled studies, 
eight done using BOTOX®, and ﬁ  ve with Dysport®. Pre-and 
post-treatment ratings were performed with one of three 
validated scales: the Toronto Western Spasmodic Torticollis 
Scale (TWSTRS) (Consky and Lang 1994), the Tsui scale 
(Tsui et al 1996), and the Cervical Dystonia Severity Scale 
(CDSS) (Brashear et al 1998). TWSTRS is rated in increasing 
severity from 0–87, summed from three subsets for pain 
(0–20), disability (0–23), and severity (0–25). The Tsui scale 
measures severity based on presence of head tremor, degree 
of postural impairment, and spasmodic or continuous quality 
of the dystonia from 0 (no impaiment) to 25 (severe impair-
ment). The CDSS charts the progression of dystonia in three 
planes based on angle of deviation from the normal. Studies 
variably utilized electromyographic (EMG) guidance to help 
target muscles. A variety of dosing schemes and injection 
strategies were used.
The metanalysis (Costa et al 2005) pooled data from the 
relevant trials to ﬁ  nd a mean two to three point improve-
ment on the Tsui scale at peak effect, with odds ratio (OR) 
vs placebo at 95% conﬁ  dence interval favoring BoNT-A of 
8.16 for a one point improvement of Tsui scale, OR 4.25 
for a three point improvement of Tsui scale, and OR 5.47 
for any improvement on either the Tsui scale or TWSTRS. 
Adverse events were reported as mild to moderate, tran-
sient or intermittent, with an overall OR of 2.1 vs placebo. 
The highest likelihood events were again neck weakness 
(OR 4.9) and dysphagia (OR 3.9). Subgroup analysis of 
BOTOX® vs placebo and Dysport® vs placebo showed no 
statistically signiﬁ  cant differences between the two BoNT-A 
formulations in efﬁ  cacy or side effects. Trends for dosing 
were analyzed, and trials involving larger doses of either 
formulation (BOTOX®: > 200U, Dysport® >960U) suggested 
increased efﬁ  cacy but a larger incidence of adverse effects, 
particularly for Dysport®.
Although BoNT-A has statistically proven clinical 
improvement for treatment of neck dystonia, the disorder is 
quite heterogeneous in both presentation and therapy solu-
tions and several questions remain unresolved. Like other 
dystonias, dosing strategies should be modiﬁ  ed based on 
severity and muscle involvement. Experienced clinicians 
note a mean total of 200U of BOTOX® or 500U Dysport® 
as effective in cervical dystonias (Jancovic 2004a), but this 
reﬂ  ects stable doses rather than starting dosing, and varies 
signiﬁ  cantly per patient. Careful examination and observa-
tion of the abnormal movements and postures are essential 
for developing a successful treatment algorithm (Jancovic 
2004b). The WEMOVE® website (http://www.wemove.org 
or http://www.mdvu.org) is an excellent tool replete with 
anatomical diagrams and dosing recommendations for CD 
and other dystonias. Nevertheless, a standardized dosing 
regimen of 500U Dysport in moderate to severe CD has 
demonstrated safety and efﬁ  cacy over a ten week period 
(Wissel et al 2001).
Primary non-response, duration of effect, and long-term 
results of BoNT-A treatment of CD have been studied. 
Although the majority of patients respond to their ﬁ  rst dose 
of BoNT-A, approximately 15% fail to derive signiﬁ  cant 
improvement of their cervical dystonia. Non-response is 
reported by patients as the primary reason for discontinuation 
of BoNT-A treatment (Brashear, Bergan et al 2000). Primary 
non-responders with longstanding dystonia may have ﬁ  brous 
contractures of neck muscles with rheological changes of 
soft tissue and muscle, creating ﬁ  xed postures not amenable 
to neuromuscular blockade. Anterocollis with inaccessible 
prevertebral muscle involvement responds poorly to treatment 
(Comella and Thompson 2006). Inaccurate muscle targeting 
and insufﬁ  cient dosing have also been cited as reasons for 
primary non-response. (Jancovic 2004a) Length of effect has 
been assessed with retrospective chart review of 60 patients 
treated for twelve or more months showed a single injection 
beneﬁ  t duration of 12.2–24.3 (mean 15.4) weeks (Brashear, 
Watts et al 2000). Comparison of Dysport® and BOTOX® 
showed average duration of improvement, as measured by 
Tsui scores as 83.9 days (Dysport®) and 80.7 days (BOTOX®) Neuropsychiatric Disease and Treatment 2007:3(6) 791
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(Odergren et al 1998). Repeated BoNT-A injections for CD 
indicate continued good response in 63% of patients treated 
over ten years (Hsuing et al 2002); secondary non-response 
was seen in only 7.5%.
EMG guidance of BoNT-A injections for CD is contested. 
Many of the potentially involved musces of the neck, par-
ticularly the scalenes, levator scapulae, and the splenius and 
semispinalis muscles are quite deep with accuracy impaired 
using only surface landmarks for localization. A study of 
needle placement without EMG guidance showed inaccurate 
placement in the sternocleidomastoid and the levator scapulae 
in 17% and 57% of all attempts, respectively (Speelman and 
Brans 1995). A randomized study of 52 CD patients receiving 
BoNT-A injections with and without EMG-guidance showed 
a statistically greater degree of beneﬁ  t and number of patients 
beneﬁ  ting from EMG-guided injections (Comella et al 1992). 
Jancovic contends that the degree of beneﬁ  t is likely minimal 
relative to a general BoNT-A response rate of 85%, and may 
not justify the added expense and patient discomfort of EMG 
(Jancovic 2004b).
Limb dystonias
Focal dystonias of the upper and lower extremities are 
particularly well-suited to treatment with localized injections 
of BoNT-A. Systemic medications carry unwanted central 
nervous system side effects and are generally ineffective. 
BoNT-A has the advantage of being a targeted, minimally 
invasive, reversible therapy, acting at the site of muscle 
dysfunction with few side effects.
Clinical trials of BoNT-A have focused largely on occu-
pational dystonias, especially writer’s cramp (WC). Most 
studies were open-label, case-controlled, or reports of clinical 
experience with a number of patients. In one double-blinded, 
placebo-controlled trial (Tsui et al 1993), 12/20 WC sufferers 
experienced improved pen control after BoNT-A injections, but 
only 4/20 noted improved writing ability. A prospective study 
of 47 patients assessed after BoNT-A injection (Djebbari et al 
2004) concluded that patients with forearm pronation and ﬂ  ex-
ion dystonias had the most improvement of their WC. Clinical 
experience suggests that most patients (75%–80%) have onset 
of beneﬁ  t one week following BoNT-A injection, peaking at 
two weeks, and lasting 3 months (Das et al 2006). The majority 
return and continue to have beneﬁ  t with repeated injections over 
years (Hsuing et al 2002). Indeed, physiologic studies suggest 
that successive BoNT-A injections for WC may effect reorga-
nization in the premotor cortex (Byrnes et al 1998).
Leg and foot dystonias are far less common and less 
well-studied. Case series of primary foot dystonia patients 
showed improvement to repeated BoNT-A injections in 
6/8 (Schneider et al 2006). Four patients with primary foot 
dystonias received signiﬁ  cantly greater beneﬁ  t from BoNT-
A injections than oral pharmacotherapies in a retrospective 
review (Singer and Papapetropoulos 2006).
The administration of BoNT-A therapy for limb dysto-
nias, like other focal dystonias, should tailor localization and 
dose to the individual movements through careful observa-
tion and examination. EMG is an invaluable adjunct for 
muscle localization, as more than half of non-EMG guided 
BoNT-A injections for limb dystonias may be inaccurately 
placed (Molloy et al 2002). EMG recording during the 
task associated with dystonia may be helpful to pinpoint 
muscle activation patterns (Karp 2004). Injections for WC 
are usually focused on ﬁ  nger ﬂ  exors and extensors in the 
forearm, but wrist pronators and ﬂ  exors are often involved 
(Das et al 2006). Dosing ranges from 10–50U BOTOX® 
and 30–120U Dysport® (Das et al 2006) per muscle. Hand 
intrinsic muscles may require smaller doses. Lower limb 
dystonias often present with foot inversion, toe dorsiﬂ  exion, 
and/or ankle plantar ﬂ  exion. Injected muscles may include 
tibialis posterior, extensor hallucis longus, gastrocnemius, 
and long toe ﬂ  exors.
Spasticity
Central nervous system disorders with upper motor neuron 
dysfunction often produce spasticity, hypertonia of the limb 
that is distinguished from rigidity by being both velocity-
dependent (Lance 1980) and dependent on range of motion. 
The muscles most prominently affected are those inner-
vated by the pyramidal tracts. In the upper extremities, the 
shoulder adductors, elbow ﬂ  exors, wrist pronators, ﬁ  nger 
and thumb ﬂ  exors are most involved (Mayer et al 1997). 
In the lower extremities, hip adductors (often resulting in 
hygiene issues), knee extensors, and ankle plantar ﬂ  exors 
and inverters may have increased spastic tone (Pathak et al 
2006). The most common causes of spasticity in adults 
are trauma, stroke, and multiple sclerosis, while in chil-
dren, cerebral palsy (CP) is the primary culprit (Jancovic 
2004a). Treatment is aimed at prevention of contractures 
and improved functional outcome (Brin et al 1997). Similar 
to dystonias, oral medications may have some beneﬁ  t, but 
produce sedation or other cognitive side effects in patients 
who may have (Dones et al 2006). Intrathecal baclofen has 
advantages in reduced dosing and likely fewer cognitive 
effects, but requires surgery for initial placement and is 
reserved for those with more generalized severe spasticity 
(Albright et al 2003).Neuropsychiatric Disease and Treatment 2007:3(6) 792
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Adult spasticity
BoNT-A has been studied as a spasticity treatment in adults. 
Most studies assessed pre- and post-treatment muscle tone 
via Ashworth scores. Many were performed in conjunction 
with electrical stimulation, and physical or occupational 
therapies. Upper limb tone has been shown in blinded, 
placebo-controlled studies to improve with 200–300U 
BOTOX® (Brashear et al 2002; Simpson et al 1996) and up 
to 1000U Dysport® (Hesse et al 1998); the effect is likely 
dose-dependent (Childers et al 2004). Lower extremity tone 
improved in spastic patients after BoNT-A injection, espe-
cially hip adductors (Hyman et al 2000) and calf spasticity 
(Mancini et al 2005). Higher doses (1000U Dysport® or 
500U BOTOX®) had signiﬁ  cantly increased likelihood of 
adverse events. Functional improvement in spastic, paretic 
limbs evaluating dexterity and gait after BoNT-A treatment 
has been limited, at best (Sheehan 2001). The clinician-
injector is directed to the Neurotoxin Institute website (www.
neurotoxininstitute.org) which is an excellent clinical tool 
with dosing schemes, muscle localization charts, and educa-
tion materials for limb spasticity.
Pediatric spasticity
BoNT-A as a treatment for the spasticity associated with cere-
bral palsy has also been studied. Rigorous reviews identiﬁ  ed 
2 randomized, blinded, placebo-controlled trials for upper 
limb spasticity (Wasiak et al 2004) and 3 trials for lower limb 
spasticity (Ade-Hall et al 2001). One upper limb trial (Corry 
et al 1997) showed statistically signiﬁ  cant improvement at 
two weeks and three months in active range of motion and 
Ashworth score in a cohort of 14 hemiplegic CP children 
randomized to normal saline or BoNT-A (BOTOX® at 
4–7U/kg or Dysport® at 8–9U/kg). Twenty-nine children 
with hemiplegic CP randomized to occupational therapy 
with or without BOTOX® (total dose 2–6U/kg) (Fehlings 
et al 2000), trended toward favoring BoNT-A treatment, but 
did not show signiﬁ  cance in relevant outcome measures. No 
statistically signiﬁ  cant difference in outcomes was found in a 
study of twelve CP children randomized to calf injections of 
BOTOX® (3–8U/kg) in follow-up (Koman et al 1994). Two 
trials of casting vs calf injection with BoNT-A (Corry et al 
1998; Flett et al 1999) in twenty ambulant CP children each 
showed largely non-signiﬁ  cant trends favoring BoNT-A. All 
of the above trials suffered from small numbers, and non-
standardized outcome measures, decreasing the likelihood of 
signiﬁ  cance. A larger and more recent trial of 125 children 
randomized to three doses of Dysport® (10, 20, 30U/kg) 
and placebo injections to the calves showed signiﬁ  cant 
improvement in gastrocnemius shortening at 4 and 16 weeks 
(Baker et al 2002). Several very recent trials have focused on 
the combination of BoNT-A with concurrent occupational 
therapy (OT). In one study, eighty children with CP involving 
the upper limb were randomized to single dose BoNT-A 
and placebo, with further randomization for 12 weeks of 
OT in each group. While the functional outcomes were 
achieved more quickly in the BoNT-A treated groups, there 
was no difference in ﬁ  nal outcome among groups (Wallen 
et al 2007). In another study, children with hemiplegic CP 
received 4 sessions of OT and were randomized to receive 
upper limb BoNT-A. Outcome measures were assessed and 
grouped based on activity participation, body structure, 
and self-perception. All three grouped measures improved 
signiﬁ  cantly in the BoNT-A treated group over controls 
(Russo et al 2007). Despite the preponderance of results fail-
ing to show treatment effect, open label trials suggest (Yang 
et al 2003) and many clinicians feel (Verotti et al 2006) that 
BoNT-A is a useful adjunct to conventional measures for 
treatment of CP and helps to reduce the need for surgical 
interventions such as heel-cord lengthening.
Hypersecretory syndromes
Sialorrhea and hyperhidrosis are socially and physically 
awkward conditions involving secretion of ﬂ  uids mediated 
by cholinergic synapses. Primary sialorrhea may result 
from overproduction of saliva, but more often drooling 
is the sequelae of neurologic disorders with poor oral or 
swallowing control (Potulsha and Friedman 2005), such as 
parkinsonism (Lagalla et al 2006), stroke, or cerebral palsy 
(Lal and Hotaling 2006). The condition may lead to increased 
perioral skin irritation, infections, unpleasant odors, social 
embarrassment and withdrawal. Hyperhidrosis is excessive 
sweating, often in the palms and soles of the feet, but also 
in the axillary region and the face. Complications include 
skin breakdown and dehydration, with possible secondary 
infections, in addition to social and psychological difﬁ  culties. 
Available treatments for both conditions include oral anticho-
linergic medications, often with associated unwanted CNS 
side effects, and surgeries for gland or ductal resection or 
rerouting (Hockstein et al 2004), or surgical denervation.
Sialorrhea
Parasympathetic cholinergic nerve terminals at the neuro-
secretory junction are dependent on the SNARE complex 
for exocytosis of acetylcholine, which is vulnerable to the 
action of botulinum toxins (Dolly and Aoki 2006). Injec-
tion of BoNT-A into parotid and/or submandibular glands Neuropsychiatric Disease and Treatment 2007:3(6) 793
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has been studied in controlled and open-labeled settings for 
management of sialorrhea. Controlled studies of adults with 
Parkinson’s disease (Mancini et al 2003) or other neurologic 
disorders (Lipp et al 2003) found that the drooling was sig-
niﬁ  cantly reduced at follow-up of 1 week to 3 months with 
clinical measures (number of dental rolls, drooling severity 
and frequency scores). No adverse effects were reported. 
A study of 45 children with CP comparing BOTOX® at 
15–25U/gland with scopolamine (Jongerius et al 2004) 
showed similar efﬁ  cacy among the two groups with fewer 
side effects from BOTOX®. Consensus for optimal dos-
ing remains elusive, with wide ranges for both parotid 
(5–75U BOTOX®, 10–145U Dysport®) and submandibular 
(5–30U BOTOX®, 70–80U Dysport®) injection (Tan 2006). 
Although some studies were done using ultrasound-guided 
techniques, ultrasound guidance may not be necessary 
for the large and superﬁ  cial parotids, and may contribute 
extra cost to an already expensive procedure (Benson and 
Daugherty 2007).
Hyperhidrosis
Sympathetic cholinergic nerve terminals in the eccrine 
and apocrine sweat glands are also amenable to botulinum 
toxin-mediated blockade (Bhidayasiri and Truong 2005). 
Axillary sweating (Lowe et al 2007) and palmar hyperhidrosis 
(Naumann and Jost 2004) treatment with BoNT-A has been 
studied in randomized clinical trials with objective and 
subjective measures conﬁ  rming safety and efﬁ  cacy. The effect 
of BoNT-A for palmar or axillary hyperhidrosis lasts for a 
mean of 7 months (Eisenach et al 2005). A trial comparing 
50U BOTOX® and 150U Dysport® (Talarico-Filho et al 2007) 
found no difference in efﬁ  cacy or duration of treatment effect 
for axillary hyperhydrosis. Palmar hyperhidrosis requires 
higher doses (120U–220U BOTOX®) due to larger surface 
area, and a greater number of injections (Naumann and 
Jost 2004). Adverse effects can include considerable pain 
necessitating local anesthesia (Benohanian 2007) or nerve 
block (Campanati et al 2004) and intrinsic hand muscle 
weakness. Topical use of botulinum toxin has been suggested 
for hyperhidrosis as well (Lim et al 2006). A pilot study using 
topical BOTOX® (mixed with a proprietary transport peptide) 
at 200U per axilla reduced absolute sweat amount by 40% 
relative to placebo at 4 weeks (Glogau 2007). Uncontrolled 
trials of injected subcutaneous BoNT-A indicate single dose 
efﬁ  cacy in Frey’s syndrome (gustatory sweating due to aber-
rant facial nerve reinnervation (Reich and Grill 2005)) for 
an average of one year with optimum dosing of BOTOX® at 
3U/cm2 affected skin (Nolte et al 2004).
Pain syndromes
Chronic headache and low back pain are two commonly 
seen complaints in the neurologist’s ofﬁ  ce. Both involve at 
least subjective muscular overactivity, particularly the band-
like bitemporal tightening of tension headache, and lumbar 
muscular spasms.
Treatment of these conditions has been difﬁ  cult, requiring 
multiple approaches with both acute and chronic pharmaco-
therapies and adjunctive measures (Jabbari and Ney 2004; 
Garza and Swanson 2006).
Botulinum toxin and pain
BoNT-A as a mediator of pain relief is a subject of consid-
erable speculation, but both central and peripheral nervous 
system actions have been hypothesized (Lang 2003; Borodic 
et al 2001). The known effect of BoNT-A at the neuromuscu-
lar junction has considerable implications in treating pain of 
muscular origin. The activation of poorly myelinated group III 
and unmyelinated group IV afferents (a large fraction of which 
are nociceptors (Borodic et al 2001)) with overactivation of 
alpha motor neurons produces abnormal patterns of muscle 
contraction, resulting in spasm and cramping (Schomburg 
et al 1999). In diminishing synaptic acetylcholine, the co-
release of local factors for nociceptive transmission, such as 
calcitonin-gene-related protein (CGRP), glutamate, substance 
P and bradykinin (Arezzo 2002), is reduced as well.
Altered function of wide dynamic range (WDR) neurons in 
the central nervous system may also play a role in pain sensiti-
zation (Graven-Nielsen and Mense 2001). Chronic pathologic 
conditions can create a failure of stimulus discrimination in 
WDR neurons. Non-painful stimuli may be perceived as caus-
ing pain. As a wider range of peripheral inputs are perceived as 
painful, nociception becomes exaggerated (Craig 2003). BoNT-A 
diminishes non-nociceptive stimuli (such as muscle spindle 
discharges (Roberts 1986)) to WDR neurons, attenuating pain 
perception. Additionally, BoNT-A may alter post-ganglionic 
cholinergic ﬁ  bers within blood vessels following neuromuscu-
lar injection. This may reduce ischemia and prevent sensitiza-
tion of muscle nociception by local factors. BoNT-A reduction 
in peripheral glutamatergic pain modulation may also play a 
role (Cui et al 2004). Neuroplastic mechanisms within the CNS 
respond to the alteration of stimuli through these mechanisms 
and the chronic pain state may be ameliorated (Filippi et al 
1993; Mannion and Woolf 2000).
Headache
Anecdotal evidence of botulinum toxin efﬁ  cacy in headache 
has been present since early uses in ocular disorders (Dutton Neuropsychiatric Disease and Treatment 2007:3(6) 794
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and Fowler 2007). A number of blinded, placebo-controlled 
studies have looked at the use of BoNT-A in headache disor-
ders, particularly migraine and chronic tension-type headache 
(CTTH). Evers and Oelsen (Evers and Oelsen 2006) recently 
reviewed the results of these studies and concluded that 
although two of nine studies showed some positive results 
(Barrientos and Chana 2003; Silberstein et al 2000), that statis-
tical review of the majority of trials failed to show a signiﬁ  cant 
treatment effect. Unfortunately, uniform dosing protocols and 
injection sites have not been developed, so dismissal of BoNT-A 
as a prophylactic treatment for headache may be premature 
(Mauskop 2007). Ultimately, clinical experience suggests that 
patient selection is important, and a greater focus on the subset 
characteristics of patients who respond to BoNT-A therapy 
may provide insight for future trials (Evers 2006).
Low back pain
Low back pain is exceedingly common and debilitating, 
and has been demonstrated in limited studies to respond to 
BoNT-A (Difazio and Jabbari 2002). Foster et al (2001) 
conducted a randomized, placebo-controlled, double-
blinded study of Botulinum toxin A versus saline injection 
in 31 patients with unilateral or predominantly unilateral 
low back pain. Patients were evaluated by quantitative and 
qualitative pain measures at baseline, three weeks and two 
months. After injection into paravertebral muscles 73% of 
enrollees at 3 weeks and 60% of enrollees at two months 
had a signiﬁ  cant response. Limitations of this study were 
the small size of cohort (15 patients received 200 units 
of BOTOX®) and the short duration of observation. The 
authors reported no signiﬁ  cant side effects. Ney and Jab-
bari demonstrated efﬁ  cacy in an open-labeled with repeated 
injections of BoNT-A in patients with initial good-response 
over a six and fourteen-month time frame (Jabbari et al 
2006; Ney et al 2006; Rotenberg et al 2006).
While these studies are encouraging, larger placebo-
controlled trials are needed, especially in light of the greater 
quantity and thus higher cost of neurotoxin that is required 
for these lower spinal muscles. Clinically, Jabbari and Ney 
(2004) suggest trigger point-injections of the low back, 
using 40–50U BOTOX® per injection in four to ﬁ  ve sites on 
each side of the spine. They report a beneﬁ  cial effect within 
7–10 days, lasting 3–4 months.
Other uses of botulinum toxin A
BoNT-A is becoming the tool of a wide range of medi-
cal specialties, often as a part of a multidisciplinary effort 
involving neurologists and other sub-specialists. Movement 
and behavioral disorders such as essential tremor (Brin et al 
2001), tic disorder (Porta et al 2004), and bruxism (Van 
Zandijcke and Marchau 1990) have all been the subject of 
BoNT-A treatment trials. Otolaryngologists and neurologists 
have long used BoNT-A for the treatment of spasmodic dys-
phonia (Blitzer 2005), but hypersecretion due to excessive 
lacrimation (Unal et al 2003; Keegan et al 2002) or rhinitis 
has also been addressed anecdotally and in treatment trials. 
Neuro-urologic/procotologic uses in anal ﬁ  ssure (Madalinski 
and Chodorowski 2006) and bladder emptying disorders 
(Patel and Chappel 2006) are established. The role of BoNT-A 
for facial cosmesis is well-known and well-publicized with 
reduction in glabellar lines and facial rhytides (Flynn 2006) 
(Table 2).
Future directions
The uses of BoNT-A discussed in this review is by no means 
exhaustive, and research into new mechanisms of action 
as well as new clinical applications is only growing. Suc-
cess with conditions of muscle overactivity due to central 
nervous system dysfunction lends BoNT-A to conditions 
with a possible psychological component such as temporal-
mandibular joint dysfunction (Schwartz and Freund 2002), 
vaginismus (Ghazizadeh and Nikzad 2004), and anismus 
(Ron et al 2001). Experimental reduction in pain-related 
behavior in rodents pre-treated with BoNT-A has suggested 
mechanisms of analgesia in inﬂ  ammatory and neuropathic 
pain in sensory neurons independent of action at the neu-
romuscular junction (Cui et al 2004; Aoki 2005; Luvisetto 
et al 2007), discussed above. BoNT-A for perioperative pain 
(Davies et al 2003), treatment for amputation stump-related 
and phantom-limb pain (Kern et al 2003), plantar fasciitis 
(Babcock et al 2005), carpal tunnel related-pain (Tsai et al 
2006), and even refractory restless-legs syndrome (Rotenburg 
et al 2006) have been reported. Botulinum toxins may have 
a role in electrodiagnosis, using BoNT-A pretreatment to 
reduce electromyographic frontotemporal artifact in electro-
encephalographic localization of aberrant cerebral discharges 
(Grant and Hermanowicz 2007). Lastly, direct infusion of 
botulinum toxin A has been shown in vivo to inhibit enzymes 
responsible for hippocampal cell death following induced 
seizures in rats (Manno et al 2007). Hence, in addition to 
its role at the neuromuscular junction and peripheral nerve, 
BoNT-A may be a neuroprotective agent for the central 
nervous system. With the all of the current interest and 
speculation in botulinum neurotoxins, one can only assume 
that a myriad exciting new therapeutic applications will come 
to light in the decades.Neuropsychiatric Disease and Treatment 2007:3(6) 795
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Table 2 Web resources for botulinum neurotoxin A
Name URL  Sponsor/Afﬁ  liate  Dosing  Localization  Patient
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